Hong Kong Pharma Stocks Surge! Hengrui Pharma Jumps 11% After Earnings, BrainAurora Doubles in 5 Days! Is a Rebound Rally Starting? 520880 Underlying Index Attracts Over 100 Million Yuan in a Single Day

Hong Kong Stocks Close Mixed: Hang Seng Edges Up 0.23% as AI Hardware, Physical AI and Innovative Drug Stocks Rally Sharply

Hengrui Presents 64 Oncology Studies at ESMO Congress 2026

Hong Kong Pharma Stocks Rally as Strong Q3 Earnings Lift Sector; Hengrui Pharma Jumps Over 12%

CATL Signs MOU with INTILION; Hengrui Pharma's First Three Quarters Net Profit Up 20.38% Year-on-Year; Li Ning Management Plans to Discuss Special Dividend

Hengrui Pharma Q3 2026 Net Profit Attributable to Shareholders Jumps 89% to RMB 2.46 Billion

Hengrui Pharma Q3: Where Will the Next Wave of Growth Come From?

Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

JPMorgan Chase & Co's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 9.74% on Oct 22 from 10.26% - HKEX

HENGRUI PHARMA's Class 1 Innovative Drug Remimazolam Tosilate for Injection Gains Approval for New Indication

Jiangsu Hengrui Pharmaceuticals Co Ltd - Nmpa Approved Additional Indication for Remimazolam Tosilate for Injection

Jiangsu Hengrui Pharmaceuticals Q3 Net Profit up 88.9% Y/Y

HENGRUI PHARMA Reports Nine-Month Net Profit of RMB 6.923 Billion, Up 20.38% Year-on-Year

Jiangsu Hengrui Pharmaceuticals 9M Revenue RMB 24,408.8 Million

AH Premium Statistics for October 26: Northeast Electric Tops Premium Rankings

New Growth Drivers Take Center Stage as China's Economy Accelerates

Hengrui Pharma Gets China Nod For Phase 3 Trial of Prostate Cancer Drug

Jiangsu Hengrui Files HKEX Next Day Disclosure Return Announcing Share Buyback

Hengrui Pharma's 64 Oncology Research Findings Accepted for ESMO 2026

Major Drugmakers Turn to China for Licensing Deals